Gubra A/S Logo

Gubra A/S

ISIN: DK0062266474 | Ticker: GUBRA | LEI: 254900T17RRFZONO6W53
Sector: Health CareSub-Industry: Biotechnology
Country: Denmark

About Gubra A/S

Company Description

Gubra, founded in 2008 in Denmark, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. Gubra’s activities are focused on the early stages of drug development and are organised in two business areas - CRO Services and Discovery & Partnerships (D&P). The two business areas are highly synergistic and create a unique entity capable of generating a steady cash flow from the CRO business while at the same time enjoying biotechnology upside in the form of development milestone payments and potential royalties from the D&P business.

Year founded

2008

Served area

Worldwide

Headcount

200

Headquarters

Hørsholm Kongevej 11B, 2970 Hørsholm – Denmark

Financial statements

Download as Excel
Line item in (dkk) 01.01.2022 01.07.2022 01.01.2023 01.07.2023
Assets N/A N/A 262,902,000.00 623,417,000.00
Noncurrent Assets N/A N/A 70,888,000.00 83,754,000.00
Land And Buildings N/A N/A 12,635,000.00 9,176,000.00
Intangible Assets Other Than Goodwill N/A N/A 7,330,000.00 10,084,000.00
Deferred Tax Assets N/A N/A 3,759,000.00 7,113,000.00
Longterm Deposits N/A N/A 4,063,000.00 4,089,000.00
Current Assets N/A N/A 192,014,000.00 539,663,000.00
Current Trade Receivables N/A N/A 36,093,000.00 24,389,000.00
Current Prepayments N/A N/A 9,941,000.00 3,937,000.00
Other Current Receivables N/A N/A 5,136,000.00 7,223,000.00
Other Current Financial Assets N/A N/A 65,664,000.00 420,611,000.00
Cash and cash equivalents 115,785,000.00 90,479,000.00 71,925,000.00 83,503,000.00
Equity And Liabilities N/A N/A 262,902,000.00 623,417,000.00
Equity 151,463,000.00 86,479,000.00 108,207,000.00 506,428,000.00
Issued Capital N/A N/A 133,000.00 16,350,000.00
Retained Earnings N/A N/A 108,074,000.00 490,078,000.00
Liabilities N/A N/A 154,695,000.00 116,989,000.00
Noncurrent Liabilities N/A N/A 60,962,000.00 67,412,000.00
Other Noncurrent Liabilities N/A N/A 0.00 848,000.00
Current Liabilities N/A N/A 93,733,000.00 49,576,000.00
Trade And Other Current Payables To Trade Suppliers N/A N/A 10,592,000.00 6,768,000.00
Current Deferred Income Including Current Contract Liabilities N/A N/A 3,171,000.00 3,444,000.00
Current Contract Liabilities N/A N/A 31,851,000.00 17,926,000.00
Current Tax Liabilities Current N/A N/A 4,437,000.00 2,216,000.00
Other Current Liabilities N/A N/A 16,198,000.00 11,488,000.00
Line item in (dkk) 01.01.2022/
01.07.2022
01.01.2023/
01.07.2023
Revenue 97,683,000.00 101,817,000.00
Other Income 975,000.00 1,086,000.00
Profit Loss From Operating Activities -9,021,000.00 -22,810,000.00
Finance Income 12,000.00 2,540,000.00
Finance Costs 938,000.00 2,871,000.00
Profit Loss Before Tax -9,946,000.00 -23,142,000.00
Income Tax Expense Continuing Operations -3,092,000.00 -5,003,000.00
Profit (loss) -6,854,000.00 -18,139,000.00
Line item in (dkk) 01.01.2022 01.07.2022 01.01.2023 01.07.2023
Profit (loss) N/A -6,854,000.00 N/A -18,139,000.00
Other Adjustments For Noncash Items N/A 21,846,000.00 N/A 5,750,000.00
Interest Paid Classified As Operating Activities N/A 986,000.00 N/A 299,000.00
Interest Received Classified As Operating Activities N/A 12,000.00 N/A 1,140,000.00
Income Taxes Paid Refund Classified As Operating Activities N/A 912,000.00 N/A 2,221,000.00
Cash Flows From Used In Operating Activities N/A 55,494,000.00 N/A -13,645,000.00
Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities N/A 0.00 N/A 5,000,000.00
Other Cash Payments To Acquire Equity Or Debt Instruments Of Other Entities Classified As Investing Activities N/A 0.00 N/A 419,335,000.00
Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities N/A 0.00 N/A 65,664,000.00
Purchase Of Property Plant And Equipment Classified As Investing Activities N/A 5,504,000.00 N/A 1,111,000.00
Cash Flows From Used In Investing Activities N/A -7,409,000.00 N/A -362,528,000.00
Proceeds From Issuing Shares N/A 0.00 N/A 500,000,000.00
Payments To Acquire Or Redeem Entitys Shares N/A 4,539,000.00 N/A 124,000.00
Repayments Of Borrowings Classified As Financing Activities N/A 1,078,000.00 N/A 0.00
Payments Of Lease Liabilities Classified As Financing Activities N/A 1,761,000.00 N/A 3,451,000.00
Dividends Paid Classified As Financing Activities N/A 66,013,000.00 N/A 68,310,000.00
Cash Flows From Used In Financing Activities N/A -73,391,000.00 N/A 387,721,000.00
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes N/A -25,306,000.00 N/A 11,547,000.00
Effect Of Exchange Rate Changes On Cash And Cash Equivalents N/A 0.00 N/A 31,000.00
Cash and cash equivalents 115,785,000.00 90,479,000.00 71,925,000.00 83,503,000.00

Please note that some sums might not add up.

Filings & Publications

Insider Trades

Sign up and we will give you access!

Capital markets information

ISIN

DK0062266474

LEI

254900T17RRFZONO6W53

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Sub-Industry

Biotechnology

Listed Stock Exchange

Nasdaq Copenhagen

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.